Polatuzumab
- Generic Name
- Polatuzumab
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)High Grade B Cell Lymphoma
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT06765317
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma
- Conditions
- LymphomaLymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Jennifer Crombie, MD
- Target Recruit Count
- 41
- Registration Number
- NCT05800366
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Lazaros Lekakis
- Target Recruit Count
- 22
- Registration Number
- NCT05260957
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
- Conditions
- LymphomaNon-Hodgkin LymphomaDiffuse Large B-Cell LymphomaBurkitt Lymphoma
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04739813
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.